DUPAGE MEDICAL TECHNOLOGY, INC.
M3mP6, a peptide inhibitor of G13-integrin signaling designed to prevent ischemia/reperfusion injury and microvascular thrombosis in myocardial infarction
- Sector
- Biotech
- Headquarters
- Willowbrook, IL
- Total capital
- $5.7M
- Federal grants
- $5.7M
- 7 awards · 2018–2025
- Rank in peer group#128 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 3 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · A new drug to treat transplant-associated renal ischemia-reperfusion injury$307K
- Federal grantHealth and Human S · Phase II · Targeting integrin outside-in signaling for treating sepsis$582K
- Federal grantHealth and Human S · Phase II · Developing a new drug for treating myocardial ischemia/reperfusion injury$1.1M
- Federal grantHealth and Human S · Phase II · Targeting integrin outside-in signaling for treating sepsis$635K
- Federal grantHealth and Human S · Phase II · Developing a new drug for treating myocardial ischemia/reperfusion injury$2M
- Federal grantHealth and Human S · Phase II · Targeting integrin outside-in signaling for treating sepsis$777K
- Federal grantHealth and Human S · Phase I · Targeting integrin outside-in signaling for treating sepsis$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#128 · top 25%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 3- PendingMethod Of Manufacturing Peptide NanoparticlesUSPTOApplication 17802917
- PendingMethod Of Manufacturing Peptide NanoparticlesUSPTOApplication PCTUS2021020263
- PendingMethod Of Manufacturing Lipid-stabilized High-loading Peptide NanoparticlesUSPTOApplication 62983425
Related companies, and why
- Genvor IncSimilar federal contract value in Biotech · null in contracts
- LAURENT PHARMACEUTICALS INC.Similar federal contract value in Biotech · null in contracts
- Chinook TherapeuticsSimilar federal contract value in Biotech · null in contracts
- SEEDLING BIOSYSTEMS INC.Similar federal contract value in Biotech · null in contracts
- CREATIVE BIOTHERAPEUTICS, LLCSimilar federal contract value in Biotech · null in contracts
- ReEngage Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .